share_log

AbbVie Chart Reflects Bearish Signals Ahead Of Q3 Earnings

AbbVie Chart Reflects Bearish Signals Ahead Of Q3 Earnings

艾伯維公司圖表顯示第三季度收益前出現消極信號
Benzinga ·  10/29 12:15

AbbVie Inc (NYSE:ABBV) will be reporting its third-quarter earnings on Wednesday. Wall Street expects $2.92 in EPS and $14.28 billion in revenues as the company reports before market hours.

艾伯維公司(紐交所:ABBV)將於週三發佈第三季度收益報告。華爾街預計每股收益爲2.92美元,營收爲142.8億美元,因公司將在市場開盤前發佈業績。

Ahead of its third-quarter earnings report, AbbVie bolstered its Alzheimer's research efforts with the $1.4 billion acquisition of Aliada Therapeutics, announced on Monday.

在第三季度業績公佈之前,艾伯維公司以14億美元收購Aliada Therapeutics加強其阿爾茨海默病研究。該交易於週一宣佈。

Aliada brings an innovative approach to delivering treatments directly to the brain, with its lead drug candidate, ALIA-1758, showing promise for Alzheimer's. This drug, still in early testing, targets amyloid beta plaques associated with the disease and could enhance AbbVie's portfolio in neuroscience.

Aliada公司採用創新方法直接向大腦傳遞治療方案,其主力藥物候選ALIA-1758在阿爾茨海默病治療方面顯示了潛力。這種藥物目前仍處於早期測試階段,針對與該疾病相關的澱粉樣蛋白斑塊,並可能增強艾伯維公司在神經科學領域的產品組合。

With the acquisition, AbbVie aims to fast-track therapies for Alzheimer's and other neurological conditions. Investors seemed to approve, as AbbVie's shares closed 1% higher on the news.

通過這一收購,艾伯維公司旨在加快阿爾茨海默病和其他神經病症的治療進程。投資者似乎對此表示贊同,因爲艾伯維公司股價在這一消息公佈後上漲了1%。

The stock is up 33.68% over the past year, 18.68% YTD.

該股過去一年上漲了33.68%,截至目前年初漲幅爲18.68%。

Let's look at what the charts indicate for AbbVie stock and how the stock currently maps against Wall Street estimates.

讓我們看看圖表顯示艾伯維公司股票的情況,以及該股目前如何與華爾街預期相匹配。

Read Also: FDA Approves AbbVie's Parkinson's Treatment, Medicare Coverage Expected Next Year

閱讀更多:FDA批准艾伯維公司的帕金森病治療方案,預計下一年醫保覆蓋。

AbbVie Stock Technical Setup Ahead Of Q3 Earnings

艾伯維公司第三季度業績前技術設置

AbbVie's technical indicators currently reflect a mixed but overall bearish trend.

艾伯維公司的技術指標目前顯示出一種混合但總體上是看淡的趨勢。

big

Chart created using Benzinga Pro

使用Benzinga Pro創建的圖表

The stock trades below its five, 20 and 50-day exponential moving averages, pointing to ongoing downward pressure.

該股票交易價格低於其五、20和50日指數移動平均線,表明持續下行壓力。

However, with a share price of $189.57, just above its eight-day SMA of $188.60, AbbVie flashes a bullish signal in the short term. The 20-day and 50-day SMAs of $191.51 and $193.71 remain above the current price, reinforcing a bearish stance in the medium term.

然而,以189.57美元的股價,略高於188.60美元的八日簡單移動平均線,艾伯維公司的短期顯示出買入信號。20日和50日的簡單移動平均線分別爲191.51美元和193.71美元,高於當前價格,強調了中期的看淡立場。

Meanwhile, the stock's position above the 200-day SMA of $177.29 offers a longer-term bullish outlook. The MACD indicator at a negative 1.35 aligns with the short-term bearish trend, though the RSI at 45.07 suggests AbbVie stock is neutral. However, a decline of the RSI below 30 could signal a potential for a reversal.

與此同時,股價高於177.29美元的200日簡單移動平均線,顯示出長期的買入前景。MACD指標爲-1.35,與短期看淡趨勢一致,儘管45.07的相對強弱指數表明艾伯維公司股票是中立的。然而,RSI低於30可能暗示着可能出現轉向。

Overall, while the technical outlook leans bearish, signs of buying pressure hint at a possible bullish turn ahead.

整體而言,儘管技術前景偏向看淡,但購買壓力的跡象暗示可能會出現看好的轉機。

AbbVie Analysts See Over 10% Upside

艾伯維公司分析師看到超過10%的上漲空間

Ratings & Consensus Estimates: The consensus analyst rating on AbbVie stock stands at a Buy with a price target of $185.11. The latest analyst ratings from Citigroup, BofA Securities, and BMO Capital give AbbVie Inc. a $210 average price target, suggesting a 10.58% upside.

評級與一致預估:艾伯維公司的共識分析師評級爲買入,目標股價爲185.11美元。花旗集團、美銀證券和蒙特利爾銀行資本的最新分析師評級給予艾伯維公司210美元的平均目標股價,顯示10.58%的上漲空間。

ABBV Price Action: AbbVie stock is down 0.12% to $189.45 at the time of publication Tuesday.

ABBV股價走勢:艾伯維公司股價在週二發佈時下跌0.12%,至189.45美元。

  • AbbVie Is Doing 'Very Well' But Jim Cramer's Favorite? Abbott Laboratories
  • 艾伯維公司表現"非常好",但吉姆·克雷默最喜歡的是雅培

Photo: Shutterstock

Photo: shutterstock

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論